Alongside our lead candidate BTM-3566, our Discovery unit is uncovering other potential small molecules using our unique scientific expertise.
We are exploring new pathways uncovered by our novel mechanism of action to identify new targets for drug development, validating new biomarkers for clinical use.
Our strategy will enable us to develop a pipeline of future indications in selected solid and hematological tumors, opening the doors to new compounds and patient populations experiencing severe unmet need. We are currently progressing another potential candidate, BTM-3528, through our development pipeline.
